{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:55:54Z","timestamp":1790564154720,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundamental Research Program of Shanxi Province","award":["202403021221211"],"award-info":[{"award-number":["202403021221211"]}]},{"DOI":"10.13039\/501100003398","name":"Shanxi Scholarship Council of China","doi-asserted-by":"publisher","award":["2023-158"],"award-info":[{"award-number":["2023-158"]}],"id":[{"id":"10.13039\/501100003398","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Provincial Natural Science Foundation of China","award":["2024J011281"],"award-info":[{"award-number":["2024J011281"]}]},{"name":"Fujian Provincial Clinical Medical Research Center for First Aid and Rehabilitation in Orthopaedic Trauma","award":["2020Y2014"],"award-info":[{"award-number":["2020Y2014"]}]},{"name":"Shanxi Provincial Department-Municipal Key Laboratory Cultivation Base for Quality Enhancement and Utilization of Shangdang Chinese Medicinal Materials","award":["KFKT202601"],"award-info":[{"award-number":["KFKT202601"]}]},{"name":"Lhasa Science and Technology Plan Project","award":["LSKJ202609"],"award-info":[{"award-number":["LSKJ202609"]}]},{"DOI":"10.13039\/501100018543","name":"Natural Science Foundation of Tibet Autonomous Region","doi-asserted-by":"publisher","award":["XZ202601ZR0176"],"award-info":[{"award-number":["XZ202601ZR0176"]}],"id":[{"id":"10.13039\/501100018543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Projects of XizangAutonomous Region","award":["XZ202602YD0009"],"award-info":[{"award-number":["XZ202602YD0009"]}]},{"name":"University-Level Scientific Research Project of Xizang University of Tibetan Medicine","award":["2026ZDZX02"],"award-info":[{"award-number":["2026ZDZX02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Astragaloside IV (AS-IV), a bioactive saponin from Astragalus membranaceus, shows promise for treating metabolic dysfunction-associated steatotic liver disease (MASLD), though its mechanisms remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to elucidate how AS-IV alleviates hepatic steatosis, specifically investigating its epigenetic regulation of lipogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using high-fat diet-fed mice and lipids-loaded hepatocytes, we assessed AS-IV's effects through SREBP-1c overexpression, histone acetylation analysis, and GCN5 rescue experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AS-IV significantly reduced hepatic steatosis by suppressing SREBP-1c-mediated de novo lipogenesis. Mechanistically, it inhibited histone acetyltransferase GCN5, decreasing H3K9\/H3K14 acetylation at the SREBP-1c promoter and attenuating LXR\u03b1-driven transcription. GCN5 overexpression reversed AS-IV's suppression of SREBP-1c and lipid accumulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AS-IV uniquely downregulates GCN5 expression at the transcriptional level, exerting epigenetic regulation to disrupts lipogenic programming, This represents a novel multi-target approach against MASLD that connects natural product pharmacology with epigenetic modulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01491-0","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:38:11Z","timestamp":1790563091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Astragaloside IV improves MASLD via GCN5-LXR\u03b1\/SREBP1c signaling pathway-mediated hepatic de novo lipogenesis"],"prefix":"10.1186","volume":"21","author":[{"given":"Hui-Mei","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Tao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Na","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Guo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"2","key":"1491_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41575-022-00717-4","volume":"20","author":"MV Machado","year":"2023","unstructured":"Machado MV, Cortez-Pinto H. NAFLD, MAFLD and obesity: brothers in arms? Nat Rev Gastroenterol Hepatol. 2023;20(2):67\u20138.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"1491_CR2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s12072-024-10660-y","volume":"18","author":"J Zhao","year":"2024","unstructured":"Zhao J, Liu L, Cao Y-Y, Gao X, Targher G, Byrne CD, et al. MAFLD as part of systemic metabolic dysregulation. Hepatol Int. 2024;18(Suppl 2):834\u201347.","journal-title":"Hepatol Int"},{"key":"1491_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01058-8","author":"Z Sun","year":"2025","unstructured":"Sun Z, Zheng Y. Metabolic diseases in the East Asian populations. Nat Rev Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1038\/s41575-025-01058-8.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"1491_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, Cao Y-Y, Zheng M-H. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35(8):697\u2013707.","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"1491_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","volume":"24","author":"A Do","year":"2025","unstructured":"Do A, Zahrawi F, Mehal WZ. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov. 2025;24(3):171\u201389.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1491_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024;84(6):729\u201335.","journal-title":"Drugs"},{"issue":"1","key":"1491_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","volume":"13","author":"JP Arab","year":"2018","unstructured":"Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13(1):321\u201350.","journal-title":"Annu Rev Pathol"},{"key":"1491_CR8","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/apt.17930","volume":"59","author":"SK Bansal","year":"2024","unstructured":"Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH\u2013role of insulin resistance and lipotoxicity. Alim Pharmacol Ther. 2024;59:S10\u201322.","journal-title":"Alim Pharmacol Ther"},{"issue":"3","key":"1491_CR9","first-page":"437","volume":"4","author":"Y Wang","year":"2025","unstructured":"Wang Y, Xiao H, Lai L, Zheng Z. Therapeutic strategies targeting SREBP transcription factors: an update to 2024. Acta Mater Med. 2025;4(3):437\u201365.","journal-title":"Acta Mater Med"},{"issue":"5","key":"1491_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","volume":"36","author":"T Bo","year":"2024","unstructured":"Bo T, Gao L, Yao Z, Shao S, Wang X, Proud CG, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2024;36(5):947\u201368.","journal-title":"Cell Metab"},{"key":"1491_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021109","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen R. The role of SCAP\/SREBP as central regulators of lipid metabolism in hepatic steatosis. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25021109.","journal-title":"Int J Mol Sci"},{"key":"1491_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114835","volume":"165","author":"H-T Xiao","year":"2023","unstructured":"Xiao H-T, Jin J, Zheng Z-G. Emerging role of GCN5 in human diseases and its therapeutic potential. Biomed Pharmacother. 2023;165:114835.","journal-title":"Biomed Pharmacother"},{"key":"1491_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.niox.2024.10.004","volume":"153","author":"B Guo","year":"2024","unstructured":"Guo B, Ma B, Li M, Li Y, Liang P, Han D, et al. The nitration of SIRT6 aggravates neuronal damage during cerebral ischemia-reperfusion in rat. Nitric Oxide. 2024;153:26\u201340.","journal-title":"Nitric Oxide"},{"issue":"5","key":"1491_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/biof.1544","volume":"45","author":"B Chatterjee","year":"2019","unstructured":"Chatterjee B, Ghosh K, Kanade SR. Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21(CIP1) in human breast cancer cell lines. BioFactors. 2019;45(5):818\u201329.","journal-title":"BioFactors"},{"issue":"3","key":"1491_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2478\/acph-2025-0022","volume":"75","author":"H Wang","year":"2025","unstructured":"Wang H, Jiang Y, Wang S, Lu C, Tang L, Gu T, et al. Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV. Acta Pharm. 2025;75(3):309\u201329.","journal-title":"Acta Pharm"},{"key":"1491_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28166118","author":"Y Liang","year":"2023","unstructured":"Liang Y, Chen B, Liang D, Quan X, Gu R, Meng Z, et al. Pharmacological effects of astragaloside IV: a review. Molecules. 2023. https:\/\/doi.org\/10.3390\/molecules28166118.","journal-title":"Molecules"},{"issue":"10","key":"1491_CR17","first-page":"1171","volume":"23","author":"X Yu","year":"2025","unstructured":"Yu X, Han Z, Guo L, Deng S, Wu J, Pan Q, et al. The novel combination of astragaloside IV and formononetin protects from doxorubicin-induced cardiomyopathy by enhancing fatty acid metabolism. Chin J Nat Med. 2025;23(10):1171\u201382.","journal-title":"Chin J Nat Med"},{"key":"1491_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.605064","volume":"11","author":"YL Liu","year":"2020","unstructured":"Liu YL, Zhang QZ, Wang YR, Fu LN, Han JS, Zhang J, et al. Astragaloside IV improves high-fat diet-induced hepatic steatosis in nonalcoholic fatty liver disease rats by regulating inflammatory factors level via TLR4\/NF-\u03baB signaling pathway. Front Pharmacol. 2020;11:605064.","journal-title":"Front Pharmacol"},{"issue":"46","key":"1491_CR19","doi-asserted-by":"publisher","first-page":"2401311","DOI":"10.1002\/advs.202401311","volume":"11","author":"S Ouyang","year":"2024","unstructured":"Ouyang S, Zhuo S, Yang M, Zhu T, Yu S, Li Y, et al. Glycerol kinase drives hepatic de novo lipogenesis and triglyceride synthesis in nonalcoholic fatty liver by activating SREBP-1c transcription, upregulating DGAT1\/2 expression, and promoting glycerol metabolism. Adv Sci (Weinh). 2024;11(46):2401311.","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"1491_CR20","doi-asserted-by":"publisher","first-page":"G833","DOI":"10.1152\/ajpgi.90358.2008","volume":"295","author":"JM Ajmo","year":"2008","unstructured":"Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol. 2008;295(4):G833\u201342.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"1491_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1042\/CS20200986","volume":"135","author":"ME Haque","year":"2021","unstructured":"Haque ME, Jakaria M, Akther M, Cho D-Y, Kim I-S, Choi D-K. The GCN5: its biological functions and therapeutic potentials. Clin Sci (Lond). 2021;135(1):231\u201357.","journal-title":"Clin Sci (Lond)"},{"issue":"37","key":"1491_CR22","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/sj.onc.1210604","volume":"26","author":"Z Nagy","year":"2007","unstructured":"Nagy Z, Tora L. Distinct GCN5\/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene. 2007;26(37):5341\u201357.","journal-title":"Oncogene"},{"issue":"5","key":"1491_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.7150\/ijbs.7.645","volume":"7","author":"F Yap","year":"2011","unstructured":"Yap F, Craddock L, Yang J. Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int J Biol Sci. 2011;7(5):645.","journal-title":"Int J Biol Sci"},{"key":"1491_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","volume":"141","author":"X Zhu","year":"2019","unstructured":"Zhu X, Bian H, Wang L, Sun X, Xu X, Yan H, et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med. 2019;141:192\u2013204.","journal-title":"Free Radic Biol Med"},{"key":"1491_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00201","volume":"9","author":"J Li","year":"2018","unstructured":"Li J, Liu M, Yu H, Wang W, Han L, Chen Q, et al. Mangiferin improves hepatic lipid metabolism mainly through its metabolite-norathyriol by modulating SIRT-1\/AMPK\/SREBP-1c signaling. Front Pharmacol. 2018;9:201.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1491_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","volume":"17","author":"D Ferguson","year":"2021","unstructured":"Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17(8):484\u201395.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1491_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1060028020935105","volume":"55","author":"JA Dougherty","year":"2021","unstructured":"Dougherty JA, Guirguis E, Thornby K-A. A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann Pharmacother. 2021;55(1):65\u201379.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1491_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cmet.2006.04.013","volume":"3","author":"C Lerin","year":"2006","unstructured":"Lerin C, Rodgers JT, Kalume DE, Kim S-h, Pandey A, Puigserver P. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1\u03b1. Cell Metab. 2006;3(6):429\u201338.","journal-title":"Cell Metab"},{"issue":"2","key":"1491_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2020.194626","volume":"1864","author":"B Mutlu","year":"2021","unstructured":"Mutlu B, Puigserver P. GCN5 acetyltransferase in cellular energetic and metabolic processes. Biochim Biophys Acta (BBA) Gene Regul Mech. 2021;1864(2):194626.","journal-title":"Biochim Biophys Acta (BBA) Gene Regul Mech"},{"issue":"8","key":"1491_CR30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.lfs.2006.02.032","volume":"79","author":"WD Zhang","year":"2006","unstructured":"Zhang WD, Zhang C, Liu RH, Li HL, Zhang JT, Mao C, et al. Preclinical pharmacokinetics and tissue distribution of a natural cardioprotective agent astragaloside IV in rats and dogs. Life Sci. 2006;79(8):808\u201315.","journal-title":"Life Sci"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01491-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01491-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01491-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:38:13Z","timestamp":1790563093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01491-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1491"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01491-0","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal care and experimental procedures were performed in accordance with the guidelines of the Animal Ethics Committee of the China Pharmaceutical University (2024-06-017).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"223"}}